Highlights

  • Xenitra reported positive operating cash flow of A$0.8 million in Q4 FY26, improving from previous quarterly outflows.
  • Closing cash increased to A$3.79 million after positive operating cash flow and financing inflows.
  • OPAL ecosystem product sales exceeded A$1.5 million, with more than 500 distribution partners onboarded.
  • OTC expansion progressed through the Fukang acquisition and a three-year Kangsheng procurement agreement.

Xenitra Limited (ASX:XEN) shares gained 20.00% to AUD 0.0030 during afternoon session trading on 30 July 2026 after the company released its Q4 FY26 operational update and Appendix 4C quarterly cash flow report, highlighting improved cash generation, margin expansion and progress across its growth platforms.

The latest update comes as Xenitra continues reshaping its operating model, with the company reporting improvements in cash conversion, a shift toward higher-margin sales channels and further development of its OTC medicines and OPAL tokenised sales ecosystems.

Xenitra’s quarterly report highlighted a transition away from lower-margin, working-capital-intensive activities toward a more focused business structure centred around nutritionals, OTC medicines and OPAL-enabled consumer product distribution.

Cash Flow Improvement Marks Key Business Transition

A major highlight from Xenitra’s Q4 FY26 update was the improvement in operating cash flow performance.

The company generated positive operating cash flow of A$0.8 million during the quarter, representing a A$2.13 million improvement compared with the A$1.33 million operating cash outflow recorded in Q3 FY26.

Compared with Q4 FY25, operating cash flow improved by A$2.46 million from an outflow of A$1.66 million.

Xenitra stated that the improvement reflected changes in its business model, including reduced exposure to lower-margin trading activities and greater focus on higher-margin sales channels.

Customer receipts during the quarter were A$5.33 million, while product manufacturing and operating payments reduced to A$3.75 million.

The company highlighted that product manufacturing and operating payments declined 56% compared with Q3 FY26 and 77% compared with the prior corresponding period.

This resulted in improved cash conversion, with the company reporting that product and operating payments represented approximately 70% of customer receipts during Q4 FY26 compared with 109% in Q3 FY26 and 105% in Q4 FY25.

Higher-Margin Sales Mix Supports Gross Margin Improvement

Alongside improved cash generation, Xenitra reported progress in improving the quality of its sales mix.

Preliminary unaudited management accounts recorded Q4 sales of approximately A$5 million, with gross profit margin reaching approximately 16%.

This compared with gross profit margin below 5% during Q3 FY26.

The company attributed the improvement to a greater contribution from higher-margin sales channels, particularly through the OPAL sales ecosystem.

Xenitra reported Q4 sales of A$4.872 million and gross profit of A$0.792 million, compared with Q3 sales of A$8.343 million and a gross loss of A$0.019 million.

The company stated that the margin improvement demonstrates the early impact of its restructuring program and transition toward a more capital-efficient operating model.

While sales volumes declined during the quarter, Xenitra noted that the reduction was intentional as the company moderated activities that did not meet revised margin, payment term and working capital return requirements.

OPAL Ecosystem Shows Early Commercial Progress

A key component of Xenitra’s growth strategy is the OPAL RWA-tokenised sales ecosystem.

The company reported that OPAL product sales exceeded A$1.5 million during the first quarter of sales for the EZZ product range, which is exclusively distributed through the platform.

The OPAL platform was launched on 7 April 2026 following more than six months of technology development.

The ecosystem operates on BNB Chain and connects product purchases with authentication, token allocation, rewards and loyalty functions.

EZZ Life Science products became the first product range integrated into OPAL under Xenitra’s four-year global distribution partnership.

The company reported that sales exceeded A$100,000 in the first week after launch, with more than 20 distributors joining the ecosystem.

By the end of the first month, sales exceeded A$500,000 with more than 130 distributors onboarded.

Within seven weeks, cumulative sales surpassed A$1.1 million, while distributor participation exceeded 400 partners.

By the end of the quarter, sales had exceeded A$1.5 million with more than 500 distribution partners onboarded.

Xenitra stated that the network developed through OPAL can be reused for additional products and brands, reducing the time and cost required for future launches.

Biomiq Skincare Expands OPAL Brand Pipeline

Further expanding the OPAL ecosystem, Xenitra announced that Biomiq Skincare has joined the platform as the second major Australian brand.

In June 2026, the company entered a four-year agreement appointing Xenitra as exclusive distributor of Biomiq Skincare products in Greater China.

The agreement includes minimum product offtake requirements of A$5 million to retain exclusivity.

Biomiq is scheduled to become the second major brand launched through OPAL, with a target launch in August 2026.

The company stated that integrating a second brand will provide an opportunity to assess the scalability of the OPAL launch model beyond the initial EZZ product range.

The Biomiq portfolio includes more than 20 Australian-made skincare products across categories including acne care, minor skin conditions and anti-ageing applications.

OTC Medicines Platform Moves Toward Commercial Execution

Xenitra continued developing its OTC medicines strategy during the quarter following the acquisition of Hong Kong Fukang Trading Co.

The acquisition was completed on 15 April 2026 for total consideration of approximately A$97,000.

The acquisition included a Hong Kong pharmaceutical wholesale licence, licensed premises, ecommerce infrastructure, trademark, inventory and logistics arrangements.

Xenitra stated that the Fukang platform provides a compliant base for cross-border online OTC sales into mainland China and pharmaceutical wholesale activities from Hong Kong.

During Q4 FY26, the company integrated the acquired assets, progressed store operations, strengthened its specialist team and advanced discussions with OTC suppliers and channel partners.

The company expects the OTC medicines strategy to generate higher-margin opportunities through specialised products, regulated market access and value-added sales execution.

Kangsheng Agreement Provides OTC Commercial Milestone

Following the end of the quarter, Xenitra announced a three-year pharmaceutical procurement agreement with Kangsheng Hong Kong International Trading Limited.

The agreement targets minimum sales of A$12 million over three years through individual purchase orders fulfilled by Fukang.

Initial commercial orders are expected following completion of operational onboarding during Q1 FY27.

Xenitra described the agreement as the first major commercial agreement for its OTC division, moving the business area from regulatory preparation and platform establishment into commercial execution.

Kangsheng’s ecommerce and retail pharmacy distribution capabilities are expected to provide access to a broader customer network in China.

The company’s next priorities include completing onboarding, commencing initial orders, expanding its approved product catalogue and developing additional brand partnerships.

Nutritionals Business Continues as Foundation Platform

While Xenitra is increasing focus on OTC medicines and OPAL, the nutritionals business remains an established part of the company’s operating platform.

During Q4 FY26, Xenitra continued servicing nutritionals demand while applying greater discipline around sales selection, procurement commitments and working capital management.

The company’s Danone product supply agreement with Rockcheck commenced on 1 May 2026 and targets approximately A$30 million in product sales through to 30 April 2027.

The agreement also includes an option for a further three-year extension subject to performance.

Xenitra stated that the nutritionals division will continue operating as a disciplined scale business, prioritising transactions with attractive margins and payment terms.

Leaner Operating Model Supports FY27 Strategy

Xenitra continued implementing its restructuring program during FY26, aimed at simplifying operations and reducing fixed infrastructure.

The company stated that the program was designed to deliver approximately A$1 million in annualised savings compared with the previous corporate structure.

Changes included reducing duplicated functions, removing Australian office and rental costs and consolidating corporate activities.

Resources were redirected toward OTC, ecommerce, pharmaceutical and tokenisation capabilities.

The company stated that the improvement from an operating cash outflow of A$1.33 million in Q3 FY26 to positive operating cash flow of A$0.8 million in Q4 FY26 demonstrates the impact of the restructuring efforts.

Liquidity Position Strengthens Entering FY27

Xenitra ended Q4 FY26 with cash of A$3.79 million, compared with A$1.83 million at 31 March 2026.

The increase followed positive operating cash flow and net financing inflows of A$1.26 million.

During the quarter, Xenitra received A$1.25 million from equity securities issuance, while net cash from financing activities totalled A$1.26 million.

The company also completed the quarter with a A$1 million loan facility from Zoomcoo, a shareholder, for working capital purposes.

Xenitra stated that maintaining liquidity while directing investment toward activities with the clearest path to sustainable gross profit remains a priority.

About Xenitra

Xenitra Limited is a cross-border consumer goods distribution and brand acceleration company connecting international FMCG, nutritionals, OTC medicines and personal care brands with consumers in Greater China.

The company operates across B2B trading, ecommerce, retail distribution and blockchain-enabled tokenised sales through the OPAL platform.

Its strategy focuses on building commercial channels that connect global brands with Asian consumers.

What This Means for Investors?

Xenitra’s latest quarterly update highlights a significant shift in the company’s operating model, with improved cash flow, higher margins and progress across new growth platforms.

The company reported positive operating cash flow, increased liquidity and early commercial validation of OPAL through product sales and distributor growth.

With OTC medicines moving toward commercial execution following the Fukang acquisition and Kangsheng agreement, and OPAL expanding through additional brands, investor attention is likely to remain focused on execution during FY27.

The company’s ability to convert these platforms into sustainable revenue and profit growth will remain a key area of focus.